Future Oncology

Article	Citations
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	112
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	80
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	66
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	57
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	56
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	55
Correction	50
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	49
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	49
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	49
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	48
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	48
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	47
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	46
Sex bias phenomenon in oral cancer: an insight	38
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE	37
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	34
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	33
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	33
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma	32
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer	32
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	31
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	31
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	31
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	31

RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLC	30
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	29
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	29
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	29
Association of exosomal miR17-92a cluster and target genes with breast cancer risk	28
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis	28
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review	28
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database	28
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer	28
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study	28
The ‘Hit-and-Run’ Strategy and Viral Carcinogenesis	27
Pembrolizumab: First Adjuvant Immunotherapy in Renal Cell Carcinoma?	27
Real-World Cost–Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High Risk of Febrile Neutropenia	27
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients	26
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)	26
A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study	26
Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study	25
Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition	25
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E–mutant metastatic colorectal cancer	25
A Multicenter Randomized, Controlled Clinical Trial of Adjuvant Sintilimab for Esophageal Squamous Cell Carcinoma	24
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis	24
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design	24
Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer	23
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer	23
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer	23
Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?	22
The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer	22
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review	22
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer	22
Social media for healthcare professionals in oncology: results from a cross-sectional survey conducted across eight countries in Asia, Latin America, and the Middle East	22
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping	21
As a Potential Predictor of Pan-Cancer, UBE2S is Related to Tumor-Associated Macrophage Infiltration	21
An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection	21
Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers	20
Effect of preoperative peripheral blood platelet volume index on prognosis in patients with invasive breast cancer	20
Application and Prospect of Single-Cell Sequencing in Cancer Metastasis	20
The Benefit of Immunotherapy in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	20
Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice	20
Multimodal Analysis of ctDNA Methylation and Fragmentomic Profiles Enhances Detection of Nonmetastatic Colorectal Cancer	19
Intraperitoneal Infusion of Recombinant Human Endostatin Improves Prognosis in Gastric Cancer Ascites	19
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission	19
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer	18
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada	18
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01)	18
Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma	18
Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland	18
LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma	17
Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status	17
Impact of radiation dose to immune cells on survival in patients with extensive-stage small cell lung cancer receiving consolidative thoracic radiotherapy after chemoimmunotherapy	17
Lorlatinib as a treatment for ALK-positive lung cancer	17

Preferences for First-Line Treatment of Advanced Urothelial Carcinoma among US Practicing Oncologists and Patients	17
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients	17
Correction	16
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment	16
Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-	16
Association of human papillomavirus with breast cancer: a new perspective on an old debate	15
Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US	15
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study	15
Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study	15
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma	15
Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA	15
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC tri	15
Relationship Between Nurses’ Perceptions and Financial Toxicity Management in the Public Health Insurance System	14
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer	14
Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers	14
Gastric cancer in pregnancy: a review	14
Plain language summary and patient perspective of the revised STARS study: long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung ca	14
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a	14
Exploring the Connection Between Microsatellite Instability and Inflammatory Indicators in Cancers	14
Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic	14
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies	14
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia	14
Corrigendum	14
A Critical Appraisal on Cancer Prognosis and Artificial Intelligence	14
Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study	14
Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis	13
Clinical Effectiveness of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation For Lack of Blood Supply in Hepatocellular Carcinoma	13
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer	13
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial	13
Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors	13
Pediatric oncohematological exercise program in hospital: clinical trial study protocol	13
The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index	13
Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?	13
Finding the right tool for the specific task: navigating RWE tools and checklists	13
Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection	13
Co-expression of CD44v6 and MMP2 predicts lung metastasis and unfavorable prognosis in osteosarcoma	13
Outdoor air pollution and oral cancer: critical viewpoints and future prospects	13
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer	12
Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database	12
Deep learning-based multiomics integration model for predicting axillary lymph node metastasis in breast cancer	12
Ponatinib in the treatment of acute lymphoblastic leukemia	12
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: A Plain Language Summary Of The DESTINY-Gastric01 Study	12
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma	12
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis	12
CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel Disease-Specific MRI Measures of Tumor Burden	12
Thyroid cancers reveal significant age- and gender-specific associations in papillary, medullary, and multinodularity types in Ha’il, Saudi Arabia: retrospective analysis	12
Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey	12
Hypersensitivity Reactions to Asparaginase Therapy in Acute Lymphoblastic Leukemia: Immunology and Clinical Consequences	12
Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study	12
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients	12
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells	12
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey	12
Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study	12
Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants	12
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resist	11
EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics	11
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study	11
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma	11
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma	11
Benefit-Risk Trade-Offs in Treatment Choice in Advanced HER2 Negative Breast Cancer: Patient and Oncologist Perspectives	11
A real-world evaluation of the rapid diagnostic clinic roll out in South East London	11
The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy	11
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study	11
Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA	11
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study	11
Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation	11
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?	11
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis	11
Palliative and End-Of-Life Symptoms Management for Children with Diffuse Intrinsic Pontine Glioma	11
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021	10
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary	10
Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer	10
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?	10
Methylated ZNF582 as a triage marker for occult cervical cancer and advanced cervical intraepithelial neoplasia	10
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy	10
Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors	10
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence	10
Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway	10
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel	10
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies	10

CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma	10
User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol	10
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma	10
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale	10
Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma	10
Tebentafusp for the Treatment of Metastatic Uveal Melanoma	9
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer	9
NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer	9
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis	9
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer	9
Association of Polymorphisms in PIN1 with Progression And Susceptibility in Gastric Cancer	9
Research progress on the role of lipoxygenase and its inhibitors in prostate cancer	9
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion	9
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma	9
Methylation site APC 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence	9
Value of Biomarkers in Epithelial–Mesenchymal Transition Models Of Liver Cancer Under Different Interventions: A Meta-Analysis	9
Safety and efficacy of left colic artery preservation in laparoscopic anterior resection for lower rectal cancer	9
Perspective on the Risk of Suicide Associated with Oral Cancer Diagnosis	9
Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary	9
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population	8
Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer	8
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma	8
Characterization of the immune environment in pregnancy-associated breast cancer	8
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA	8
Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis	8
Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups	8
Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia	8
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China	8
Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched stud	8
Real-world Management Patterns in EGFR -mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece	8
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?	8
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort	8
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma	8
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy	8
Extended distal pancreatectomy in pancreatic cancer: is it justified? A systematic review of literature	8
The Role of Surgery in Metastatic Cancer: The Case For a Pragmatic Tumor-Agnostic Randomized Trial	8
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial	8
Correction	8
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary	8
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma	8
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review	8
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)	8
LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers	8
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006	8
Development and validation of a Cancer Patient Suicidal Ideation Scale	8
Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked	8
Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force	8
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data	8
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101	8
Prognostic Value of GPC5 Polymorphism rs2352028 and Clinical Characteristics in Chinese Lung Cancer Patients	8
PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer	7
How I treat Ph+ acute lymphoblastic leukemia	7
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases	7
A plain language summary of LocoMMotion – an observational study of treatments used for pretreated multiple myeloma	7
Corrigendum	7
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma	7
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma	7
Effect of Lateral Lymph Nodes Without Malignant Characteristics on the Prognosis of Patients with Rectal Cancer	7
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	7
Selpercatinib in the treatment of thyroid cancer	7
Corrigendum	7
Nab-paclitaxel vs paclitaxel liposome for advanced breast cancer: real-world efficacy and safety analysis	7
Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey	7
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors	7
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations	7
Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study	7
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study	7
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China	7
Frontline anti-PD-1/PD-L1 Versus Bevacizumab in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis	7
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study	7
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	7
The impact of myelosuppression on quality of life of patients treated with chemotherapy	7
Clinical Application of Serum Tumor Abnormal Protein Combined with Tumor Markers in Lung Cancer Patients	7
Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule	7
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis	7
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer	7
Margetuximab in HER2-positive metastatic breast cancer	7
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary	7
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary	7
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences	7
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	7
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	7
The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)	7
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	7
Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment	6
SOLTI-1904 ACROPOLI TRIAL: Efficacy of Spartalizumab Monotherapy Across Tumor-Types Expressing High Levels of PD1 mRNA	6
The Genetic Polymorphisms in the SP4 Gene and the Risk of Gastric Cancer	6
Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial	6
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe	6
Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma	6
An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ	6
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer	6
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial	6
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success	6
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer	6